Translational reprogramming in tumour cells can generate oncoselectivity in viral therapies

Area of Science:

• Oncology
• Molecular Biology
• Gene Therapy

Background:

• Systemic cancer treatments necessitate tumor-selective therapies to minimize damage to healthy tissues.
• Tumorigenesis involves significant translational reprogramming, making translational control a promising avenue for oncoselective therapies.
• Reactivation of mRNA translational control by cytoplasmic polyadenylation element-binding proteins (CPEBs) in cancer was recently identified.

Purpose of the Study:

• To develop a novel strategy for restricting gene-engineered therapies to malignant tissues.
• To exploit CPEB translational regulation for enhancing the oncoselectivity of therapeutic agents.

Main Methods:

• Engineered oncolytic adenoviruses by inserting CPE regulatory sequences into the 3'-untranslated region of the E1A gene.
• Investigated the modulation of tumor-specific expression of viral proteins through CPEB-mediated mRNA stability and translational regulation.
• Assessed the oncoselectivity and potency of engineered viruses in cancer versus normal tissues.

Main Results:

• Demonstrated that CPEB translational regulation can be harnessed to control tumor-specific expression of viral proteins.
• Engineered oncolytic adenoviruses exhibited oncoselectivity, showing full potency in cancer cells and attenuated activity in normal tissues.
• Insertion of CPE regulatory sequences conferred tumor-selectivity to the oncolytic adenoviruses.

Conclusions:

• The presented strategy offers a novel approach to improve the design of oncolytic viruses for enhanced tumor selectivity.
• This framework provides a method for exploiting CPE-regulated transgenes in the development of targeted cancer therapies.
• The findings highlight the potential of translational control mechanisms for developing safer and more effective cancer treatments.